Genovis AB (publ.) (FRA:5GV)

Germany · Delayed Price · Currency is EUR

1.806

+0.018 (1.01%)

Last updated: Dec 5, 2025, 8:03 AM CET

-13.79% (1Y)

Market Cap	123.14M
Revenue (ttm)	10.64M
Net Income (ttm)	1.92M
Shares Out	n/a
EPS (ttm)	0.03
PE Ratio	64.26
Forward PE	44.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	1.806
Previous Close	1.788
Day's Range	1.806 - 1.806
52-Week Range	1.526 - 2.580
Beta	n/a
RSI	45.36
Earnings Date	Feb 12, 2026

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1999

Employees 32

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 5GV

Full Company Profile

Financial Performance

In 2024, Genovis AB (publ.)'s revenue was 131.32 million, a decrease of -17.44% compared to the previous year's 159.07 million. Earnings were 32.92 million, a decrease of -46.48%.

Financial numbers in SEK Financial Statements

News

There is no news available yet.